Udenafil is a PDE5 inhibitor used to treat erectile dysfunction. It has been approved in South Korea and will be marketed under the brand name Zydena.
- Mechanism
- Curator reviewed
Udenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by udenafil enhances erectile function by increasing the amount of cGMP.
- Primary indication
- Investigated for use/treatment in erectile dysfunction and hypertension.Curator reviewed · 2 structured indications
- Formula / weight
- C25H36N6O4S · 516.656 g/mol (avg)
- Code names
- DA-8159
Resolves to
IYFNEFQTYQPVOC-UHFFFAOYSA-NSMILESCCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2CWhat you can answer from here — as of November 06, 2025
Which drugs share a target with Udenafil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account